


REVISED PROGRAMS

Breast:

Effective **1 October 2024**, requisition of the Oncotype DX® Breast Cancer Assay will no longer require the approval of the BC Cancer Compassionate Access Program (CAP). The process has been revised as below. More detailed information can be found on the BC Cancer website at: <http://www.bccancer.bc.ca/lab-services-site>



- Clinicians submit a signed patient consent form via fax or DocuSign to the Exact Sciences.
- For patients who does not meet eligibility, clinicians may submit CAP as outlined in the [BCCA Compassionate Access Program \(CAP\) Policy \(III-45\)](#).